DUBLIN – Genmab A/S's Duobody bispecific antibody technology received a stamp of approval from the big Kahuna of Danish biopharmas, Novo Nordisk A/S, which is in-licensing two programs that address two different target combinations, in a deal potentially worth up to $500 million in development, regulatory and sales milestones, as well as $2 million up front.